Holen Sie sich die Stockscreener-App
1.05
4.55%
-0.05
Vorhandelsmarkt:
1.08
0.03
+2.86%
Lucid Diagnostics Inc Aktie (LUCD) Neueste Nachrichten
Lucid Diagnostics Holds Annual Stockholders Meeting - TipRanks
Leading California Hospital Network Launches Revolutionary 3-Minute Cancer Detection Test from Lucid Diagnostics - Stock Titan
119,887 Shares in Lucid Diagnostics Inc. (NASDAQ:LUCD) Acquired by Citadel Advisors LLC - Defense World
Ascendiant Capital Markets Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price - Defense World
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 By Investing.com - Investing.com South Africa
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 - Investing.com Australia
Lucid Diagnostics (LUCD) Stock Maintained at Buy by Ascendiant Capital | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Target Price Increased by Ascendiant | - GuruFocus
Lucid Diagnostics Files For Offering Of 36 Million Shares Of Common Stock - MarketScreener
Pavmed's Veris Health Signs Long-Term Partnership Deal With Ohio State University Hospital - marketscreener.com
Lucid Diagnostics Enters $25M Sales Agreement - TipRanks
Lucid Diagnostics joins Russell 2000 and 3000 indexes - Mugglehead Magazine
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes - The Malaysian Reserve
Lucid Diagnostics to Join Russell 2000, Russell 3000 Indexes - marketscreener.com
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com South Africa
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes - Investing.com Australia
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Indexes | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Ind - GuruFocus
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.50 Consensus Price Target from Brokerages - Defense World
Certain Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - marketscreener.com
Certain Common Stock of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - marketscreener.com
Insider Buying: Dennis Matheis Acquires 350,000 Shares of Lucid Diagnostics Inc (LUCD) - GuruFocus
Certain Series B-1 Convertible Preferred Stock of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - MarketScreener
Lucid Diagnostics (LUCD) Director Acquires Significant Shares | - GuruFocus
Lucid Diagnostics (LUCD) Director Acquires Significant Shares | LUCD Stock News - GuruFocus
Lucid Diagnostics Joins Elite Russell Indexes, Opens Door to $10.6T Investment Pool - Stock Titan
Lucid Diagnostics Files Shelf Registration for Secondary Sale of 37 Million Shares by Convertible Note Holders - marketscreener.com
Lucid Diagnostics (LUCD) Files to Sell 36.98 Million Shares | LU - GuruFocus
Lucid Diagnostics Files Prospectus For Potential Offer, Sale From Time To Time Of Up To 37 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
Lucid Diagnostics (LUCD) Files to Sell 36.98 Million Shares | LUCD Stock News - GuruFocus
Lucid Diagnostics’ SWOT analysis: stock faces reimbursement hurdles amid market potential - Investing.com Nigeria
Cantor Fitzgerald maintains Lucid Diagnostics stock Overweight - Investing.com Australia
Cantor Fitzgerald maintains Lucid Diagnostics stock Overweight By Investing.com - Investing.com India
Lucid Diagnostics’ (LUCD) Buy Rating Reiterated at Needham & Company LLC - Defense World
Cantor Fitzgerald Reiterates “Overweight” Rating for Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Lucid Diagnostics (LUCD) Stock Rating Reiterated by Cantor Fitzg - GuruFocus
Lucid Diagnostics signals expanded market reach and $41M pro forma cash following commercial and clinical advances - MSN
Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NUVB), Lucid Diagnostics (LUCD) and Arcellx Inc (ACLX) - The Globe and Mail
Lucid Diagnostics Reports Increased Losses Amid Revenue Decline - TipRanks
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates - MSN
Cantor maintains Lucid Diagnostics stock with $2 target after Q1 results - Investing.com Australia
Lucid Diagnostics (LUCD) Stock Rating Reiterated by Cantor Fitzgerald | LUCD Stock News - GuruFocus
Transcript : PAVmed Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
PAVmed Inc Q1 2025 Earnings: Revenue Surges to $0.8 Million, Bea - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 F - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results | PAVM Stock News - GuruFocus
0.54%
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):